Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (GB:0QOK)
LSE:0QOK
Holding GB:0QOK?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025Before Open Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
CHF8.39Last Year’s EPS
CHF8.47Same Quarter Last Year
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jul 25, 2024
|% Change Since: -8.00%
|Next Earnings Date:Jan 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in core business areas, significant regulatory achievements, and innovative product launches, particularly in diagnostics and ophthalmology. However, the decline in COVID-related sales and loss of exclusivity posed challenges, alongside some setbacks in clinical trials. Overall, the sentiment leans towards positive due to robust performance in key segments and promising future growth drivers.Company Guidance
During the ROG.SW Earnings call for Q2 2024, Roche Group executives provided comprehensive guidance and metrics highlighting their performance and strategic initiatives. Group sales increased by 8% overall, with a significant 9% growth in Q2. The Pharma division grew by 8%, while Diagnostics saw a 9% increase, excluding COVID-19 impacts. The core operating profit surged by 11%, bolstered by effective cost management, leading to a 2 percentage point rise in operating margins. Core earnings per share (EPS) and operating cash flow both grew by 9%. Key regulatory milestones included EU approvals for Ocrevus and Alecensa, and U.S. approval for PiaSky. The company also filed for new indications, expecting approvals for inavolisib by November. Roche is optimistic about its obesity treatment pipeline, with strong Phase I results for CT-388 and CT-996. The Diagnostics division is introducing new products like the cobas lead respiratory panel and Accu-Chek SmartGuide CGM. Looking forward, Roche aims to maintain strong growth in its base business, with high single-digit growth projected for core EPS. The company emphasizes operational excellence and strategic resource allocation to ensure sustained performance.Strong Growth in Core Business
Group sales increased by 8% excluding COVID, with Pharma growing by 8% and Diagnostics by 9%.
Record Operating Profit and Margin Improvement
Core operating profit increased by 11%, with a 2 percentage point increase in core operating margin.
Significant Regulatory Achievements
Received EU approval for Ocrevus subcut in RMS and PPMS, Alecensa in adjuvant non-small cell lung cancer, and FDA label update for Susvimo in AMD.
Innovative Product Launches in Diagnostics
Launch of cobas lead respiratory panel and continuous glucose monitoring system, among others.
Growth in Ophthalmology Franchise
Vabysmo achieved 54% growth, with increasing market share in key regions.
---
GB:0QOK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0QOK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jul 25, 2024 | CHF272.40 | CHF278.53 | +2.25% |
| Feb 01, 2024 | CHF238.05 | CHF227.58 | -4.40% |
| Jul 27, 2023 | CHF260.25 | CHF260.94 | +0.26% |
| Feb 02, 2023 | CHF260.37 | CHF253.58 | -2.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roche Holding AG (GB:0QOK) report earnings?
Roche Holding AG (GB:0QOK) is schdueled to report earning on Jan 30, 2025, Before Open Not Confirmed.
What is Roche Holding AG (GB:0QOK) earnings time?
Roche Holding AG (GB:0QOK) earnings time is at Jan 30, 2025, Before Open Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Roche Holding AG stock?
The P/E ratio of Roche Holding AG is 18.8.
What is GB:0QOK EPS forecast?
GB:0QOK EPS forecast for the fiscal quarter 2024 (Q4) is CHF8.39.
---